A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies

Cancer Research

Volumn 74, Issue 4, 2014, Pages 1179-1189

  Green, Damian J ^a   Orgun, Nural N ^a   Jones, Jon C ^a   Hylarides, Mark D ^a   Pagel, John M ^a   Hamlin, Donald K ^b   Wilbur, D S ^b   Lin, Yukang ^a   Fisher, Darrell R ^c   Kenoyer, Aimee L ^a   Frayo, Shani L ^a   Gopal, Ajay K ^a   Orozco, Johnnie J ^a   Gooley, Theodore A ^a   Wood, Brent L ^a   Bensinger, William I ^a   Press, Oliver W ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c Dade Moeller Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD38; CELLS, CULTURED; FEMALE; HETEROCYCLIC COMPOUNDS; HUMANS; MICE; MICE, NUDE; MICE, TRANSGENIC; MOLECULAR TARGETED THERAPY; NEOPLASMS, PLASMA CELL; ORGANOMETALLIC COMPOUNDS; RADIOIMMUNOTHERAPY; XENOGRAFT MODEL ANTITUMOR ASSAYS; YTTRIUM RADIOISOTOPES;

EID: 84894264467     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-1589     Document Type: Article

References (50)

1. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516-20.
2. Anderson KC. The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma. J Clin Oncol 2012;30:445-52.
3. Pilarski LM, Hipperson G, Seeberger K, Pruski E, Coupland RW, Belch AR. Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice. Blood 2000;95: 1056-65.
4. Matsui W, Wang Q, Barber JP, Brennan S, Smith BD, Borrello I, et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res 2008;68:190-7.
5. Nademanee A, Forman S, Molina A, Fung H, Smith D, Dagis A, et al. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 2005;106: 2896-902.
6. Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autol-ogous bone marrow support. N England J Med 1993;329:1219-24.
7. Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, Zasadny K, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N England J Med 2005;352:441-9.
8. Kumar S. Solitary plasmacytoma: is radiation therapy sufficient? Am J Hematol 2008;83:695-6.
9. Gluck S, Van Dyk J, Messner HA. Radiosensitivity of human clonogenic myeloma cells and normal bone marrow precursors: effect of different dose rates and fractionation. Int J Radiat Oncol, Biol, Phys 1994; 28:877-82.
10. Giralt S, Bensinger W, Goodman M, Podoloff D, Eary J, Wendt R, et al. 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials. Blood 2003;102:2684-91.
11. Rousseau C, Ferrer L, Supiot S, Bardies M, Davodeau F, Faivre-Chauvet A, et al. Dosimetry results suggest feasibility of radioimmu-notherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients. Tumour Biol 2012;33:679-88.
12. Goel A, Dispenzieri A, Geyer SM, Greiner S, Peng KW, Russell SJ. Synergistic activity of the proteasome inhibitor PS-341 with non-myeloablative 153-Sm-EDTMP skeletally targeted radiotherapy in an orthotopic model of multiple myeloma. Blood 2006;107:4063-70.
13. Kapoor P, Greipp PT, Morice WG, Vincent Rajkumar S, Witzig TE, Greipp PR. Anti-CD20 monoclonal antibody therapy in multiple myeloma. British J Haematol 2008;141:135-48.
14. Supiot S, Faivre-Chauvet A, Couturier O, Heymann MF, Robillard N, Kraeber-Bodere F, et al. Comparison of the biologic effects of MA5 and B-B4 monoclonal antibody labeled with iodine-131 and bismuth-213 on multiple myeloma. Cancer 2002;94:1202-9.
15. Deaglio S, Aydin S, Vaisitti T, Bergui L, Malavasi F. CD38 at the junction between prognostic marker and therapeutic target. Trends Mol Med 2008;14:210-8.
16. Bataille R, Jego G, Robillard N, Barille-Nion S, Harousseau JL, Moreau P, et al. The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy. Haematologica 2006;91:1234-40.
17. Fernandez JE, Deaglio S, Donati D, Beusan IS, Corno F, Aranega A, et al. Analysis of the distribution of human CD38 and of its ligand CD31 in normal tissues. J Biol Regul Homeost Agents 1998;12:81-91.
18. Su A, MacLeod WC. BioGPS. [Cited 2012 May 9]. Available from: http://biogps.org/gene/952/.
19. de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DCH, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 2011;186:1840-8.
20. Tesar M. Fully human antibody MOR202 against CD38 for the treatment of multiple myeloma and other blood-bourne malignancies. J Clin Oncol 2007;25:8106.
21. Vooijs WC, Schuurman HJ, Bast EJ, de Gast GC. Evaluation of CD38 as target for immunotherapy in multiple myeloma. Blood 1995;85: 2282-4.
22. Goldmacher VS, Bourret LA, Levine BA, Rasmussen RA, Pourshadi M, Lambert JM, et al. Anti-CD38-blocked ricin: an immunotoxin for the treatment of multiple myeloma. Blood 1994;84:3017-25.
23. Bolognesi A, Polito L, Farini V, Bortolotti M, Tazzari PL, Ratta M, et al. CD38 as a target of IB4 mAb carrying saporin-S6: design of an immunotoxin for ex vivo depletion of hematological CD38 neoplasia. J Biol Regul Homeost Agents 2005;19:145-52.
24. Goldenberg DM, Chang CH, Sharkey RM, Rossi EA, Karacay H, McBride W, et al. Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods? Eur J Nucl Med Mol Imaging 2003;30:777-80.
25. Forero A, Weiden PL, Vose JM, Knox SJ, LoBuglio AF, Hankins J, et al. A Phase I trial of a novel anti-CD20 fusion protein in pretargeting radioimmunotherapy for B cell non-Hodgkin's lymphoma. Blood 2004;104:227-36.
26. Axworthy DB, Fritzberg AR, Hylarides MD, Mallett RW, Theodore LJ, Gustavson LM, et al. Preclinical evaluation of an anti-tumor monoclonal antibody/streptavidin conjugate for pretargeted Y-90 radioimmu-notherapy in a mouse xenograft model. J Immunother. 1994;16:158.
27. Press OW, Corcoran M, Subbiah K, Hamlin DK, Wilbur DS, Johnson T, et al. A comparative evaluation of conventional and pretargeted radio-immunotherapy of CD20-expressing Lymphoma Xenografts. Blood 2001;98:2535-43.
28. Graves SS, Dearstyne E, Lin Y, Zuo Y, Sanderson J, Schultz J, et al. Combination therapy with pretarget CC49 radioimmunotherapy and gemcitabine prolongs tumor doubling time in a Murine Xenograft model of colon cancer more effectively than either monotherapy. Clin Cancer Res 2003;9:3712-21.
29. Schultz J, Lin Y, Sanderson J, Zuo Y, Stone D, Mallett R, et al. A tetravalent single-chain antibody-streptavidin fusion protein for pre-targeted lymphoma therapy. Cancer Res 2000;60:6663-9.
30. Mirzadeh S, Brechbiel MW, Atcher RW, Gansow OA. Radiometal labeling of immunoproteins: covalent linkage of 2-(4-isothiocyanato-benzyl) diethylenetriaminepentaacetic acid ligands to immunoglobulin. Bioconjugate Chem 1990;1:59-65.
31. Park SI, Shenoi J, Frayo SM, Hamlin DK, Lin Y, Wilbur DS, et al. Pretargeted radioimmunotherapy using genetically engineered anti-body- streptavidin fusion proteins for treatment of non-hodgkin lym-phoma. Clin Cancer Res 2011;17:7373-82.
32. Pressman D, Day ED, Blau M. The use of paired labeling in the determination of tumor-localizing antibodies. Cancer Res 1957;17: 845-50.
33. Fisher DR, Shen S, Meredith RF. MIRD dose estimate report no. 20: radiation absorbed-dose estimates for 111In-and 90Y-ibritumomab tiuxetan. J Nucl Med 2009;50:644-52.
34. Hui TE, Fisher DR, Kuhn JA, Williams LE, Nourigat C, Badger CC, et al. A mouse model for calculating cross-organ beta doses from yttrium-90-labeled immunoconjugates. Cancer 1994;73:951-7.
35. Beatty BG, Kuhn JA, Hui TE, Fisher DR, Williams LE, Beatty JD. Application of the cross-organ beta dose method for tissue dosimetry in tumor-bearing mice treated with a 90Y-labeled immunoconjugate. Cancer 1994;73:958-65.
36. Press OW, Shan D, Howell-Clark J, Eary J, Appelbaum FR, Matthews D, et al. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res 1996;56:2123-9.
37. Press OW, Howell-Clark J, Anderson S, Bernstein I. Retention of B-cell-specific monoclonal antibodies by human lymphoma cells. Blood 1994;83:1390-7.
38. Paganelli G, Grana C, Chinol M, Cremonesi M, De Cicco C, De Braud F, et al. Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. Eur J Nucl Med 1999;26:348-57.
39. DeNardo DG, Xiong CY, Shi XB, DeNardo GL, DeNardo SJ. Anti-HLA-DR/anti-DOTA diabody construction in a modular gene design platform: bispecific antibodies for pretargeted radioimmunotherapy. Cancer Biother Radiopharm 2001;16:525-35.
40. Leigh BR, Kurtts TA, Mack CF, Matzner MB, Shimm DS. Radiation therapy for the palliation of multiple myeloma. Int J Radiat Oncol Biol Phys 1993;25:801-4.
41. Bink K, Haralambieva E, Kremer M, Ott G, Beham-Schmid C, de Leval L, et al. Primary extramedullary plasmacytoma: similarities with and differences from multiple myeloma revealed by interphase cytogenet-ics. Haematologica 2008;93:623-6.
42. Berenson JR, Yellin O, Patel R, Duvivier H, Nassir Y, Mapes R, et al. A phase I study of samarium lexidronam/bortezomib combination therapy for the treatment of relapsed or refractory multiple myeloma. Clinical Cancer Res 2009;15:1069-75.
43. Green DJ, Pagel JM, Nemecek ER, Lin Y, Kenoyer A, Pantelias A, et al. Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates. Blood. 2009;114: 1226-35.
44. Subbiah K, Hamlin DK, Pagel J, Wilbur DS, Meyer DL, Axworthy DB, et al. Comparative immunoscintigraphy, toxicity, and efficacy of conventional and pretargeted radioimmunotherapy in a CD20-expressing human lymphoma xenograft model. J Nucl Med 2003;44:437-45.
45. Pagel JM, Orgun N, Hamlin DK, Wilbur DS, Gooley TA, Gopal AK, et al. A comparative analysis of conventional and pretargeted radioimmu-notherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations. Blood 2009;113:4903-13.
46. Ma D, McDevitt MR, Barendswaard E, Lai L, Curcio MJ, Pellegrini V, et al. Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies. Leukemia 2002;16:60-6.
47. Tuscano JM, O'Donnell RT, Miers LA, Kroger LA, Kukis DL, Lamborn KR, et al. Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts. Blood 2003;101: 3641-7.
48. Sharkey RM, Karacay H, Litwin S, Rossi EA, McBride WJ, Chang CH, et al. Improved therapeutic results by pretargeted radioimmunother-apy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody. Cancer Res 2008;68:5282-90.
49. LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mit-siades N, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002;62:4996-5000.
50. Lentzsch S, LeBlanc R, Podar K, Davies F, Lin B, Hideshima T, et al. Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia 2003;17:41-4.